Cargando…
Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study
OBJECTIVE: Tumor immune microenvironmental features may predict survival and guide treatment. This study aimed to comprehensively decipher the immunological features of different molecular subtypes of endometrial cancer. METHODS: In this retrospective study, 26 patients with primary endometrial canc...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756131/ https://www.ncbi.nlm.nih.gov/pubmed/36532042 http://dx.doi.org/10.3389/fimmu.2022.1035616 |
_version_ | 1784851567700082688 |
---|---|
author | Dai, Yibo Zhao, Luyang Hua, Dingchao Cui, Lina Zhang, Xiaobo Kang, Nan Qu, Linlin Li, Liwei Li, He Shen, Danhua Wang, Zhiqi Wang, Jianliu |
author_facet | Dai, Yibo Zhao, Luyang Hua, Dingchao Cui, Lina Zhang, Xiaobo Kang, Nan Qu, Linlin Li, Liwei Li, He Shen, Danhua Wang, Zhiqi Wang, Jianliu |
author_sort | Dai, Yibo |
collection | PubMed |
description | OBJECTIVE: Tumor immune microenvironmental features may predict survival and guide treatment. This study aimed to comprehensively decipher the immunological features of different molecular subtypes of endometrial cancer. METHODS: In this retrospective study, 26 patients with primary endometrial cancer and four with recurrent disease treated in our center from December 2018 to November 2021 were included. Next-generation sequencing was performed on tumor samples. Patients were classified into four subtypes, including POLE mutant, microsatellite instability high (MSI-H), no specific molecular profile (NSMP) and TP53 mutant subtypes. Tumor-infiltrating immune cells were quantified using multiplex immunofluorescence assays. RESULTS: Of the 26 primary endometrial cancer cases, three were POLE mutant, six were MSI-H, eight were NSMP and nine were TP53 mutant. Of the four recurrent cases, two belonged to the NSMP subtype and two belonged to the TP53 mutant subtype. The tumor mutation burden (TMB) levels of POLE mutant and MSI-H cases were significantly higher than that of the other two subtypes (p< 0.001). We combined POLE mutant and MSI-H subtypes into the TMB high (TMB-H) subtype. The TMB-H subtype showed a high degree of infiltration of CD8(+) T cells. In the NSMP subtype, the overall degree of intra-tumoral infiltrating immune cells was low. In the TP53 mutant subtype, the densities of both PD-L1(+) macrophages (p = 0.047) and PD-1(+) T cells (p = 0.034) in tumor parenchyma were the highest among the four subtypes. CONCLUSION: Endometrial cancer of TMB-H, NSMP and TP53 mutant subtypes displayed phenotypes of normal immune response, absence of immune infiltration, and suppressed immune response, respectively. These features may provide mechanistic explanations for the differences in patients’ prognosis and efficacy of immune checkpoint blockade therapies among different endometrial cancer subtypes. |
format | Online Article Text |
id | pubmed-9756131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97561312022-12-17 Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study Dai, Yibo Zhao, Luyang Hua, Dingchao Cui, Lina Zhang, Xiaobo Kang, Nan Qu, Linlin Li, Liwei Li, He Shen, Danhua Wang, Zhiqi Wang, Jianliu Front Immunol Immunology OBJECTIVE: Tumor immune microenvironmental features may predict survival and guide treatment. This study aimed to comprehensively decipher the immunological features of different molecular subtypes of endometrial cancer. METHODS: In this retrospective study, 26 patients with primary endometrial cancer and four with recurrent disease treated in our center from December 2018 to November 2021 were included. Next-generation sequencing was performed on tumor samples. Patients were classified into four subtypes, including POLE mutant, microsatellite instability high (MSI-H), no specific molecular profile (NSMP) and TP53 mutant subtypes. Tumor-infiltrating immune cells were quantified using multiplex immunofluorescence assays. RESULTS: Of the 26 primary endometrial cancer cases, three were POLE mutant, six were MSI-H, eight were NSMP and nine were TP53 mutant. Of the four recurrent cases, two belonged to the NSMP subtype and two belonged to the TP53 mutant subtype. The tumor mutation burden (TMB) levels of POLE mutant and MSI-H cases were significantly higher than that of the other two subtypes (p< 0.001). We combined POLE mutant and MSI-H subtypes into the TMB high (TMB-H) subtype. The TMB-H subtype showed a high degree of infiltration of CD8(+) T cells. In the NSMP subtype, the overall degree of intra-tumoral infiltrating immune cells was low. In the TP53 mutant subtype, the densities of both PD-L1(+) macrophages (p = 0.047) and PD-1(+) T cells (p = 0.034) in tumor parenchyma were the highest among the four subtypes. CONCLUSION: Endometrial cancer of TMB-H, NSMP and TP53 mutant subtypes displayed phenotypes of normal immune response, absence of immune infiltration, and suppressed immune response, respectively. These features may provide mechanistic explanations for the differences in patients’ prognosis and efficacy of immune checkpoint blockade therapies among different endometrial cancer subtypes. Frontiers Media S.A. 2022-11-24 /pmc/articles/PMC9756131/ /pubmed/36532042 http://dx.doi.org/10.3389/fimmu.2022.1035616 Text en Copyright © 2022 Dai, Zhao, Hua, Cui, Zhang, Kang, Qu, Li, Li, Shen, Wang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Dai, Yibo Zhao, Luyang Hua, Dingchao Cui, Lina Zhang, Xiaobo Kang, Nan Qu, Linlin Li, Liwei Li, He Shen, Danhua Wang, Zhiqi Wang, Jianliu Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study |
title | Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study |
title_full | Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study |
title_fullStr | Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study |
title_full_unstemmed | Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study |
title_short | Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study |
title_sort | tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756131/ https://www.ncbi.nlm.nih.gov/pubmed/36532042 http://dx.doi.org/10.3389/fimmu.2022.1035616 |
work_keys_str_mv | AT daiyibo tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT zhaoluyang tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT huadingchao tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT cuilina tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT zhangxiaobo tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT kangnan tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT qulinlin tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT liliwei tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT lihe tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT shendanhua tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT wangzhiqi tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy AT wangjianliu tumorimmunemicroenvironmentinendometrialcancerofdifferentmolecularsubtypesevidencefromaretrospectiveobservationalstudy |